Education
About Us
Working with TipRanks
Follow Us
Mineralys Therapeutics, Inc. (MLYS)
NASDAQ:MLYS
RESEARCH TOOLSreports
MLYS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.24 - $18.38
Previous CloseN/A
Volume137.34K
Average Volume (3M)891.42K
Market Cap
$1.00B
Enterprise ValueN/A
Total Cash (Recent Filing)$198.19M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Aug 11, 2025EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding65,175,285
10 Day Avg. Volume909,529
30 Day Avg. Volume891,424
Financial Highlights & Ratios
PEG Ratio0.37
Price to Book (P/B)3.91
Price to Sales (P/S)0.00
P/FCF Ratio-4.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$38.14Price Target Upside148.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Mineralys Therapeutics, Inc. News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe 50mg dose of the aldosterone synthase inhibitor demonstrated a placebo-adjusted SBP reduction of 9.1 mmHg at Week 6, which increased to an 11.70 mmHg delta at Week 12.
Financial PerformanceMineralys reported finishing the period with $343.0M in cash, cash equivalents, and investments, which is expected to fund operations into 2027.
Market PotentialAnalyst reiterates a Buy rating and sets a $42 price target, reflecting confidence in lorundrostat's differentiated profile and market potential.
Bears Say
Commercial StrategyManagement believes they can commercialize in the US themselves with a targeted approach focused on an initial base of the fourth line market.
Regulatory ChallengesManagement plans to meet with the FDA to discuss a filing, expecting the NDA package to include data from pivotal trials and supportive data from the EXPLORE-CKD trial.
---
Ownership Overview
Currently, No data available
---
MLYS FAQ
What was Mineralys Therapeutics, Inc.’s price range in the past 12 months?
Mineralys Therapeutics, Inc. lowest stock price was $8.24 and its highest was $18.38 in the past 12 months.
What is Mineralys Therapeutics, Inc.’s market cap?
Mineralys Therapeutics, Inc.’s market cap is $1.00B.
When is Mineralys Therapeutics, Inc.’s upcoming earnings report date?
Mineralys Therapeutics, Inc.’s upcoming earnings report date is Aug 11, 2025 which is in 84 days.
How were Mineralys Therapeutics, Inc.’s earnings last quarter?
Mineralys Therapeutics, Inc. released its earnings results on May 12, 2025. The company reported -$0.79 earnings per share for the quarter, beating the consensus estimate of -$0.982 by $0.192.
Is Mineralys Therapeutics, Inc. overvalued?
According to Wall Street analysts Mineralys Therapeutics, Inc.’s price is currently Undervalued.
Does Mineralys Therapeutics, Inc. pay dividends?
Mineralys Therapeutics, Inc. does not currently pay dividends.
What is Mineralys Therapeutics, Inc.’s EPS estimate?
Mineralys Therapeutics, Inc.’s EPS estimate is -0.75.
How many shares outstanding does Mineralys Therapeutics, Inc. have?
Mineralys Therapeutics, Inc. has 65,175,285 shares outstanding.
What happened to Mineralys Therapeutics, Inc.’s price movement after its last earnings report?
Mineralys Therapeutics, Inc. reported an EPS of -$0.79 in its last earnings report, beating expectations of -$0.982. Following the earnings report the stock price went up 1.199%.
Which hedge fund is a major shareholder of Mineralys Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MLYS
---
Mineralys Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.14 (148.47% Upside)
$38.14 (148.47% Upside)
Blogger Sentiment
Bullish
MLYS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 12.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $37.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.8%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.73%
12-Months-Change
Fundamentals
Return on Equity
-56.31%
Trailing 12-Months
Asset Growth
2.22%
Trailing 12-Months
Company Description
Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. (MLYS) is a biopharmaceutical company focused on developing innovative therapies for the treatment of cardiovascular and renal diseases. The company operates within the healthcare sector and specializes in the research and development of novel therapeutic solutions aimed at addressing unmet medical needs in these areas. Mineralys’ core product pipeline is centered around the development of targeted treatments that leverage its expertise in mineralocorticoid receptor biology.
---
MLYS Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant clinical and financial achievements, including successful trial results for lorundrostat, high physician interest, and strong financial backing. However, challenges remain, such as increased net loss and manageable concerns regarding hyperkalemia. Overall, the positive developments outweigh the challenges.Read More>---
MLYS Stock 12 Month Forecast
Average Price Target
$38.14
▲(148.47% Upside)
Technical Analysis
---